While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.
Steven Madden (SHOO)
Trailing 12-Month GAAP Operating Margin: 4.8%
As seen in the infamous Wolf of Wall Street movie, Steven Madden (NASDAQ: SHOO) is a fashion brand famous for its trendy and innovative footwear, appealing to a young and style-conscious audience.
Why Should You Dump SHOO?
- Muted 17% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
- Low free cash flow margin of 5.1% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
At $38.88 per share, Steven Madden trades at 1x forward price-to-sales. If you’re considering SHOO for your portfolio, see our FREE research report to learn more.
Concrete Pumping (BBCP)
Trailing 12-Month GAAP Operating Margin: 10.7%
Going public via SPAC in 2018, Concrete Pumping (NASDAQ: BBCP) is a provider of concrete pumping and waste management services in the United States and the United Kingdom.
Why Does BBCP Give Us Pause?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 5.7% annually over the last two years
- Earnings per share have dipped by 47.7% annually over the past two years, which is concerning because stock prices follow EPS over the long term
- Low returns on capital reflect management’s struggle to allocate funds effectively
Concrete Pumping is trading at $7.79 per share, or 53x forward P/E. Check out our free in-depth research report to learn more about why BBCP doesn’t pass our bar.
Labcorp (LH)
Trailing 12-Month GAAP Operating Margin: 10.2%
With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE: LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide.
Why Are We Cautious About LH?
- Annual sales declines of 1.6% for the past five years show its products and services struggled to connect with the market during this cycle
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 11.1% annually, worse than its revenue
Labcorp’s stock price of $255.05 implies a valuation ratio of 13.9x forward P/E. Dive into our free research report to see why there are better opportunities than LH.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
